SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

June 22, 2010 08:55 ET

Radient Pharmaceuticals Schedules Investor Call to Discuss Onko-Sure Commercialization Developments

TUSTIN, CA--(Marketwire - June 22, 2010) -  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today announced it will conduct a conference call to update investors on its 2010 commercialization strategy for RPC's Onko-Sure™ in vitro diagnostic (IVD) cancer test on Thursday, June 24, 2010 at 1:00 p.m. PDT/4:00 p.m. EDT. RPC's commercialization strategy for Onko-Sure is centered on establishing Onko-Sure as the preeminent cancer test for the worldwide screening, testing and diagnosis of over 13 different types of cancer.

Mr. Douglas MacLellan, Executive Chairman and CEO of Radient Pharmaceuticals, will host the call. A question and answer session will follow the main presentation and investors will be able to access presentation materials following the conference call by visiting the Investor Relations page of RPC's website at www.radient-pharma.com through July 1, 2010.

Interested investors may access the conference call by dialing (877) 360 - 1705 for domestic callers and (706) 902 - 3245 for international callers, using the conference ID 82282874 ten minutes prior to the start time of 1:00 p.m. PDT. The conference call will be downloadable at www.radient-pharma.com approximately three hours following the call.

About Onko-Sure™:
Onko‐Sure is a simple, non‐invasive, patent‐pending and regulatory‐approved IVD test for use as an aid in early detection of cancer. Onko‐Sure enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko‐Sure is approved by the US FDA for the monitoring of colorectal cancer, Health Canada as a lung cancer screen and cancer monitoring tool, and the European Union, Indian government, Korean government, and Taiwanese government as a cancer monitoring or cancer screening test. Onko‐Sure test kits are currently sold as a blood test for cancer in Europe, India, Taiwan, Korea, Vietnam and in Chile for research use.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. Our focus is on the discovery, development & commercialization of unique high‐value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko‐Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing or assist in the selection of therapy.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323